
    
      Prospective, open-label, controlled 12month observational study

      Premenopausal women with surgically verified endometriosis will receive goserelin 1 injection
      per month for 6 months. Subsequently goserelin will be discontinued and patients will be
      monitored for another 6 months after menstrual restoration. Age- and BMI-matched
      premenopausal, health women will serve as controls. Controls will receive no treatment.
    
  